Paclitaxel polymeric micelle formulation - Samyang

Drug Profile

Paclitaxel polymeric micelle formulation - Samyang

Alternative Names: Cremophor EL-free polymeric micelle of paclitaxel; Cynviloq; Genexol-PM; IG-001; NANT-008; Nant-paclitaxel; paclitaxel loaded polymeric micelle - Samyang; paclitaxel-loaded micellar diblock copolymer

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Samyang Biopharmaceuticals Corporation; Samyang Group; Sorrento Therapeutics
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase II Bladder cancer; Pancreatic cancer
  • Phase I Gynaecological cancer

Most Recent Events

  • 02 May 2017 NantPharma plans a phase I/II trial for Pancreatic cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) (NCT03127124)
  • 14 Apr 2016 Samyang Biopharmaceuticals Corporation plans a phase II trial for Pancreatic cancer (Combination therapy, Metastatic disease, Recurrent) in South Korea (IV) (NCT02739633)
  • 01 Apr 2016 Phase-I clinical trials in Gynaecological cancer (Combination therapy) in South Korea (IV) (NCT02739529)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top